论文部分内容阅读
目的探究中期妊娠产妇给予米非司酮联合米索前列醇终止妊娠的临床成效及安全性,寻找此类产妇终止妊娠最科学的医疗手段。方法选取2010年3月-2013年10月该院妇产科收治的自愿行人工引产的中期妊娠孕妇88例,随机分为研究组和对照组,每组各44例。研究组开展米非司酮联合米索前列醇引产,对照组开展利凡诺行羊膜腔内注射法引产。分析两组成功引产率、引产时间、引产出血量、引产残留物及不良反应发生率的差异。结果研究组引产成功率高于对照组,引产时间和不良反应发生率低于对照组,引产残留物少于对照组,差异均有统计学意义(P均<0.05);两组在引产出血量方面比较,差异无统计学意义(P>0.05)。结论中期妊娠妇女实施米非司酮联合米索前列醇引产能提高引产质量,缩短引产时间,安全性更佳,可取得较为满意的临床成效。
Objective To explore the clinical efficacy and safety of maternal mifepristone combined with misoprostol for terminating pregnancy in the second trimester of pregnancy and to find out the most scientific medical means for such termination of pregnancy. Methods From March 2010 to October 2013, 88 pregnant women of mid-term pregnancy were randomly divided into study group and control group, with 44 cases in each group. Study group to carry out mifepristone combined with misoprostol induction of labor, the control group to carry out rivanol line of amniotic injection induced labor. Analysis of the two groups successful induction of labor rate, induction of labor, induced labor output, induction of labor residues and the incidence of adverse reactions. Results The success rate of induction of labor in study group was higher than that of control group, and the incidence of induced labor and adverse reactions was lower than that of control group. The induced abortion was less than that of control group (all P <0.05) In terms of comparison, the difference was not statistically significant (P> 0.05). Conclusion Mifepristone combined with misoprostol induction in mid-term pregnant women can improve the quality of induced labor, shorten the time of induction of labor, better safety and achieve satisfactory clinical outcomes.